vs

Side-by-side financial comparison of SurgePays, Inc. (SURG) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.

SurgePays, Inc. is the larger business by last-quarter revenue ($16.2M vs $13.2M, roughly 1.2× TriSalus Life Sciences, Inc.). TriSalus Life Sciences, Inc. runs the higher net margin — -73.9% vs -85.6%, a 11.8% gap on every dollar of revenue. On growth, SurgePays, Inc. posted the faster year-over-year revenue change (68.7% vs 59.8%). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs -28.2%).

SurgePays, Inc. is a U.S.-headquartered fintech and telecommunications company focused on serving underbanked and low-income communities across the country. It offers prepaid wireless plans, reloadable debit cards, digital banking solutions, and daily consumer products through a nationwide network of independent local retail partners such as convenience stores.

TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.

SURG vs TLSI — Head-to-Head

Bigger by revenue
SURG
SURG
1.2× larger
SURG
$16.2M
$13.2M
TLSI
Growing faster (revenue YoY)
SURG
SURG
+8.8% gap
SURG
68.7%
59.8%
TLSI
Higher net margin
TLSI
TLSI
11.8% more per $
TLSI
-73.9%
-85.6%
SURG
Faster 2-yr revenue CAGR
TLSI
TLSI
Annualised
TLSI
43.0%
-28.2%
SURG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SURG
SURG
TLSI
TLSI
Revenue
$16.2M
$13.2M
Net Profit
$-13.9M
$-9.8M
Gross Margin
-14.8%
86.7%
Operating Margin
-79.1%
-24.8%
Net Margin
-85.6%
-73.9%
Revenue YoY
68.7%
59.8%
Net Profit YoY
30.0%
3.5%
EPS (diluted)
$-0.68
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SURG
SURG
TLSI
TLSI
Q4 25
$16.2M
$13.2M
Q3 25
$18.7M
$11.6M
Q2 25
$11.5M
$11.2M
Q1 25
$10.6M
$9.2M
Q4 24
$9.6M
$8.3M
Q3 24
$4.8M
$7.3M
Q2 24
$15.1M
$7.4M
Q1 24
$31.4M
$6.5M
Net Profit
SURG
SURG
TLSI
TLSI
Q4 25
$-13.9M
$-9.8M
Q3 25
$-7.5M
$-10.8M
Q2 25
$-7.1M
$-8.3M
Q1 25
$-7.6M
$-10.4M
Q4 24
$-19.8M
$-10.1M
Q3 24
$-14.3M
$-2.4M
Q2 24
$-12.9M
$-4.3M
Q1 24
$1.2M
$-13.2M
Gross Margin
SURG
SURG
TLSI
TLSI
Q4 25
-14.8%
86.7%
Q3 25
-13.9%
83.5%
Q2 25
-23.0%
83.9%
Q1 25
-27.8%
83.7%
Q4 24
-117.0%
85.3%
Q3 24
-164.2%
86.3%
Q2 24
-22.8%
87.6%
Q1 24
26.0%
85.0%
Operating Margin
SURG
SURG
TLSI
TLSI
Q4 25
-79.1%
-24.8%
Q3 25
-37.2%
-77.9%
Q2 25
-59.1%
-65.4%
Q1 25
-71.7%
-79.9%
Q4 24
-209.0%
-91.8%
Q3 24
-299.4%
-118.9%
Q2 24
-72.1%
-111.0%
Q1 24
5.6%
-180.8%
Net Margin
SURG
SURG
TLSI
TLSI
Q4 25
-85.6%
-73.9%
Q3 25
-40.1%
-93.5%
Q2 25
-61.5%
-73.9%
Q1 25
-72.2%
-113.2%
Q4 24
-206.5%
-122.4%
Q3 24
-299.3%
-32.6%
Q2 24
-85.3%
-58.8%
Q1 24
3.9%
-204.5%
EPS (diluted)
SURG
SURG
TLSI
TLSI
Q4 25
$-0.68
$-0.22
Q3 25
$-0.38
$-0.96
Q2 25
$-0.36
$-0.27
Q1 25
$-0.38
$-0.39
Q4 24
$-1.07
$-0.38
Q3 24
$-0.73
$-0.12
Q2 24
$-0.66
$-0.21
Q1 24
$0.07
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SURG
SURG
TLSI
TLSI
Cash + ST InvestmentsLiquidity on hand
$1.7M
$20.4M
Total DebtLower is stronger
$13.3M
Stockholders' EquityBook value
$-15.3M
$-33.9M
Total Assets
$8.5M
$35.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SURG
SURG
TLSI
TLSI
Q4 25
$1.7M
$20.4M
Q3 25
$2.5M
$22.7M
Q2 25
$4.4M
$26.5M
Q1 25
$5.4M
$13.0M
Q4 24
$11.8M
$8.5M
Q3 24
$23.7M
$11.3M
Q2 24
$16.5M
Q1 24
$4.0M
Total Debt
SURG
SURG
TLSI
TLSI
Q4 25
$13.3M
Q3 25
$12.0M
Q2 25
$9.6M
Q1 25
$3.6M
Q4 24
$4.0M
Q3 24
$4.4M
Q2 24
$4.8M
Q1 24
$5.2M
Stockholders' Equity
SURG
SURG
TLSI
TLSI
Q4 25
$-15.3M
$-33.9M
Q3 25
$-6.4M
$-26.7M
Q2 25
$116.1K
$-19.4M
Q1 25
$7.8M
$-34.4M
Q4 24
$15.3M
$-25.9M
Q3 24
$33.2M
$-20.4M
Q2 24
$46.2M
$-25.3M
Q1 24
$56.0M
$-36.0M
Total Assets
SURG
SURG
TLSI
TLSI
Q4 25
$8.5M
$35.3M
Q3 25
$14.5M
$36.5M
Q2 25
$15.2M
$41.3M
Q1 25
$15.7M
$28.6M
Q4 24
$24.0M
$24.0M
Q3 24
$41.5M
$27.5M
Q2 24
$56.4M
$32.4M
Q1 24
$69.6M
$17.9M
Debt / Equity
SURG
SURG
TLSI
TLSI
Q4 25
Q3 25
Q2 25
82.67×
Q1 25
0.46×
Q4 24
0.26×
Q3 24
0.13×
Q2 24
0.10×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SURG
SURG
TLSI
TLSI
Operating Cash FlowLast quarter
$-3.6M
$-2.5M
Free Cash FlowOCF − Capex
$-2.5M
FCF MarginFCF / Revenue
-19.1%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-19.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SURG
SURG
TLSI
TLSI
Q4 25
$-3.6M
$-2.5M
Q3 25
$-4.6M
$-3.7M
Q2 25
$-6.1M
$-7.3M
Q1 25
$-7.0M
$-4.5M
Q4 24
$-7.9M
$-5.7M
Q3 24
$-13.3M
$-10.8M
Q2 24
$-4.1M
$-13.4M
Q1 24
$4.0M
$-10.9M
Free Cash Flow
SURG
SURG
TLSI
TLSI
Q4 25
$-2.5M
Q3 25
$-3.9M
Q2 25
$-7.4M
Q1 25
$-5.3M
Q4 24
$-5.8M
Q3 24
$-11.0M
Q2 24
$-13.5M
Q1 24
$-10.9M
FCF Margin
SURG
SURG
TLSI
TLSI
Q4 25
-19.1%
Q3 25
-33.9%
Q2 25
-66.1%
Q1 25
-57.3%
Q4 24
-69.7%
Q3 24
-149.9%
Q2 24
-183.1%
Q1 24
-169.3%
Capex Intensity
SURG
SURG
TLSI
TLSI
Q4 25
0.3%
Q3 25
1.9%
Q2 25
0.8%
Q1 25
8.2%
Q4 24
0.6%
Q3 24
2.3%
Q2 24
0.8%
Q1 24
1.0%
Cash Conversion
SURG
SURG
TLSI
TLSI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
3.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons